Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism

Introduction: Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but is under-represented in trials of direct oral anticoagulants (DOACs) in venous thromboembolic disease (VTE). We aimed to assess whether the administration of DOACs was equivalent to the conventional (CONV) tre...

Full description

Bibliographic Details
Main Author: Santos, Sónia Martins (author)
Other Authors: Cunha, Susana (author), Baptista, Rui (author), Monteiro, Sílvia (author), Monteiro, Pedro (author), Gonçalves, Francisco (author), Pêgo, Mariano (author)
Format: article
Language:eng
Published: 2017
Subjects:
Anticoagulants
Venous thromboembolism
Real world
Pulmonary embolism
Intermediate-high risk
Warfarin
CHAVEAnticoagulantes
Tromboembolismovenoso
Mundo real
Embolia pulmonar
Risco intermédio aelevado
VarfarinaExperiência
Administration, Oral
Adult
Aged
Aged, 80 and over
Cohort Studies
Female
Humans
Male
Middle Aged
Pulmonary Embolism
Retrospective Studies
Risk Assessment
Young Adult
Online Access:http://hdl.handle.net/10316/102117
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/102117

Internet

http://hdl.handle.net/10316/102117

Similar Items